What if cancer cells could be re-engineered to turn against their own kind?
A new study in Science Translational Medicine, led by researchers at Brigham and Women’s Hospital, leverages the power of gene editing to take a critical step toward using cancer cells to kill cancer. The team reports promising results in preclinical models across multiple types of cancer cells, establishing a potential roadmap toward clinical translation for treating primary, recurrent and metastatic cancer.
“This is just the tip of the iceberg,” said corresponding author Khalid Shah MS, PhD, director of the Center for Stem Cell Therapeutics and Imaging (CSTI) in the BWH Department of Neurosurgery and faculty at Harvard Medical School and Harvard Stem Cell Institute (HSCI). “Cell-based therapies hold tremendous promise for delivering therapeutic agents to tumors and may provide treatment options where standard therapy has failed. With our technique, we show it is possible to reverse-engineer a patient’s own cancer cells and use them to treat cancer. We think this has many implications and could be applicable across all cancer cell types.”
The new approach capitalizes on cancer cells’ self-homing ability – the process in which cancer cells can track the cells of their kind that have spread within the same organ or to other parts of the body. Harnessing this power could overcome drug delivery challenges, helping get therapeutics to tumor sites that may otherwise be difficult to reach.
The team developed and tested two techniques to harness the power of cancer cells. The “off the shelf” technique used pre-engineered tumor cells that would need to be matched to a patient’s HLA phenotype (essentially, a person’s immune fingerprint). The “autologous” approach used CRISPR technology to edit the genome of a patient’s cancer cells and insert therapeutic molecules. These cells could then be transferred back into the patient.
To test both approaches, the team used mouse models of primary and recurrent brain cancer and breast cancer that has spread to the brain. The team saw direct migration of engineered cells to the sites of tumors and found evidence that the engineered cells specifically targeted and killed recurrent and metastatic cancer in the mice. The researchers report that the treatment increased the survival of the mice. Engineered cells were equipped with a “kill switch” that could be activated after treatment – PET imaging showed that this kill switch worked to eliminate the cells.
“Our study demonstrates the therapeutic potential of using engineered tumor cells and their self-homing properties for developing receptor-targeted therapeutics for various cancers,” said Shah.
The Latest on: Engineered cancer cells
via Google News
The Latest on: Engineered cancer cells
- Pig heart transplant failed as its heart muscle cells diedon June 24, 2022 at 10:34 am
Earlier this year, news broke of the first experimental xenotransplantation: A human patient with heart disease received a heart from a pig that had been genetically engineered to avoid rejection.
- Kiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product Candidateon June 21, 2022 at 5:19 am
IND for Non-Engineered Deltacel/KB-GDT ™ to be Submitted in the ... "Against the backdrop of a global cancer cell therapy market that’s expected to exceed $33 billion by 2027, Kiromic’s product ...
- Breakthrough study of hormone 'cross-talk' in breast canceron June 16, 2022 at 7:08 am
Scientists led by EPFL have successfully engrafted breast cancer cells on mice, allowing them to study in vivo the cross-talk between the estrogen and progesterone receptors that hampers hormone ...
- University of Michigan: $2.38M to test nano-engineered brain cancer treatment in miceon June 15, 2022 at 10:38 pm
A new nanomedicine that crosses the blood-brain barrier, engages the immune system and kills cancer cells may offer hope for treating the most aggressive form of brain cancer, glioblastoma.With $2.38 ...
- Could a One-Shot Treatment for Patients with HIV Be on the Horizon?on June 14, 2022 at 5:00 am
A new mouse study by researchers from Tel Aviv University and collaborators demonstrates a potential new treatment for AIDS which may be developed into a vaccine or a one-time treatment for patients ...
- Synthetic Receptor Could Alleviate Need for Chemo Treatment Before T-Cell Therapyon June 9, 2022 at 1:20 am
Research shows that a synthetic IL-9 receptor allows cancer-fighting T cells to do their work without the need for chemo or radiation.
- Synthetic IL-9 receptor allows T cells to fight cancer without the need for chemo or radiationon June 7, 2022 at 5:01 pm
has shown that a synthetic IL-9 receptor allows those cancer-fighting T cells to do their work without the need for chemo or radiation. T cells engineered with the synthetic IL-9 receptor ...
- Immune therapy targets cells that cause leukemia relapseon June 2, 2022 at 11:00 am
Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective ...
- Scientists discover new clues to liver cancer progressionon June 2, 2022 at 6:44 am
To find new therapeutic targets to better control tumor development, the NUS team decided to study the role of endothelial cells in cancer development using engineered in vitro tumor models.
via Bing News